4
Participants
Start Date
July 5, 2017
Primary Completion Date
February 9, 2018
Study Completion Date
February 9, 2018
Pembrolizumab
Pembrolizumab will be administered intravenously.
Sylatron
Sylatron will be administered subcutaneously.
Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
Collaborators (1)
Merck Sharp & Dohme LLC
INDUSTRY
Roswell Park Cancer Institute
OTHER
The Cleveland Clinic
OTHER
Georgetown University
OTHER
Hoosier Cancer Research Network
OTHER
Aiwu Ruth He, MD
OTHER